• The MDinteractive deadline for 2020 MIPS reporting is
    Monday, March 1, 2021.

  • MDinteractive is an approved CMS Qualified Registry for
    2020 and 2021.

  • CMS Publishes 2021 Final Rule. What will it mean for your practice?
    Check out our highlights blog here.

Patient Medication Risk Education

Activity ID

IA_PSPA_31

Activity Weighting

High

Subcategory Name

Patient Safety and Practice Assessment

Activity Description

In order to receive credit for this activity, MIPS eligible clinicians must provide both written and verbal education regarding the risks of concurrent opioid and benzodiazepine use for patients who are prescribed both benzodiazepines and opioids. Education must be completed for at least 75 percent of qualifying patients and occur:
(1) at the time of initial co-prescribing and again following greater than 6 months of co- prescribing of benzodiazepines and opioids; or
(2) at least once per MIPS performance period for patients taking concurrent opioid and benzodiazepine therapy.

Validation

Eligible clinicians and groups must provide both written and verbal education regarding the risks of concurrent opioid and benzodiazepine use for patients who are prescribed both benzodiazepines and opioids.

Suggested Documentation

Education must be completed for at least 75 percent of qualifying patients and occur as follows:
1) at the time of initial co-prescribingand again following greater than 6 months of co- prescribing of benzodiazepines and opioids, or
2)at least once per MIPSperformance period for patientstaking concurrent opioid andbenzodiazepine therapy.

Register with MDinteractive